Skip to main content
Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Fig. 5

Representative microphotographs of liver sections stained with Sirius red in the liver sections and percentage in area of positive staining for Sirius red in the five groups. Data are mean ± SD. §P < 0.05, P < 0.001 vs. vehicle; #P < 0.05 vs. Linagliptin alone; ‡‡P < 0.05 vs. Empagliflozin alone

Back to article page